P1.11-05 Application of the CRISPR/Cas9-based Gene Editing Technology for the Treatment of NUT Carcinoma

NUT carcinoma is a rare and highly aggressive form of cancer with a poor prognosis and limited treatment options. This cancer is characterized by the expression of the NUTM1 (NUT (nuclear protein in testis) family member 1) fusion protein, which is responsible for driving oncogenesis. Despite recent advances in the understanding of the molecular mechanisms underlying NUT carcinoma (NC), effective therapies for this disease are still lacking. In this study, we investigated the therapeutic potential of CRISPR/Cas9-mediated knockout of NUTM1.